Cáncer de próstata y cáncer de testículo

Abstract

Testicular cancerThis is the most common tumour between the ages of 15 and 35 years. There is a high cure rate; therefore, a prompt, multidisciplinary therapeutic approach is essential. In patients with advanced disease, treatment is based on established prognostic factors that determine life expectancy and first-line therapy. However, standard treatment has not been defined for patients in whom the disease reappears or progresses after first-line treatment. New lines of research have been opened thanks to knowledge of this tumour's molecular biology. Prostate cancerThis is the most common tumour in males. The great majority are diagnosed at local stage, in part due to PSA screening, making it possible to establish radical treatment with curative intent. However, this is a very heterogeneous disease which forces us to stratify patients into prognostic groups and thus orient treatment in the most appropriate manner. In recent years major developments have taken place to combat advanced disease, in that several drugs have been approved with different therapeutic strategies to tackle the disease.